E-LIB Suche - Ergebnisse für: Fiedler-Kelly, Jill

1

Exposure–Efficacy Analyses Support Optimal Dosing Regimens ..:

Gao, Wei ; Passarell, Julie ; Patel, Yogesh T....
Antimicrobial Agents and Chemotherapy. 66 (2022) 5 - p. , 2022

Link: https://doi.org/10.1128/..

2

Scaling Approaches for Pediatric Dose Selection: The Freman..:

Jones, Aksana ; Cohen-Barak, Orit ; Radivojevic, Andrijana.
Pharmaceutics. 13 (2021) 6 - p. 785 , 2021

Link: https://doi.org/10.3390/..

3

Concentration–QTc analysis of quizartinib in patients with ..:

Kang, Dongwoo ; Ludwig, Elizabeth ; Jaworowicz, David...
Cancer Chemotherapy and Pharmacology. 87 (2021) 4 - p. 513-523 , 2021

Link: https://doi.org/10.1007/..

4

Dose selection for fremanezumab (AJOVY) phase 3 pediatric m..:

Cohen-Barak, Orit ; Radivojevic, Andrijana ; Jones, Aksana...
Cephalalgia. 41 (2021) 10 - p. 1065-1074 , 2021

Link: https://doi.org/10.1177/..

5

Modeling and simulations to support dose selection for esli..:

Sunkaraneni, Soujanya ; Ludwig, Elizabeth ; Fiedler-Kelly, Jill...
Journal of Pharmacokinetics and Pharmacodynamics. 45 (2018) 4 - p. 649-658 , 2018

Link: https://doi.org/10.1007/..

6

Data standards for model-informed drug development: an ISoP..:

Radivojevic, Andrijana ; Corrigan, Brian ; Downie, Nicholas...
Journal of Pharmacokinetics and Pharmacodynamics. 45 (2018) 5 - p. 659-661 , 2018

Link: https://doi.org/10.1007/..

7

Physiologically-Based and Population Pharmacokinetic Modeli..:

Sunkaraneni, Soujanya ; Ludwig, Elizabeth ; Bihorel, Sebastien...
Neurology. 88 (2017) 16_supplement - p. , 2017

Link: https://doi.org/10.1212/..

8

Modeling and Simulation Strategy to Support Eslicarbazepine..:

Sunkaraneni, Soujanya ; Bihorel, Sebastien ; Hopkins, Seth...
Neurology. 88 (2017) 16_supplement - p. , 2017

Link: https://doi.org/10.1212/..

9

Prediction of efficacy for conversion from adjunctive thera..:

Sunkaraneni, Soujanya ; Passarell, Julie A ; Ludwig, Elizabeth...
Clinical Pharmacology: Advances and Applications. 9 (2017) - p. 65-72 , 2017

Link: https://doi.org/10.2147/..

10

Efficacy, safety, tolerability and population pharmacokinet..:

Ortiz-Covarrubias, Alejandro ; Fang, Edward ; Prokocimer, Philippe G....
The Brazilian Journal of Infectious Diseases. 20 (2016) 2 - p. 184-192 , 2016

Link: https://doi.org/10.1016/..

11

Population Pharmacokinetic Modeling of Armodafinil and Its ..:

Willavize, Susan ; Fiedler-Kelly, Jill ; Ludwig, Elizabeth.
The Journal of Clinical Pharmacology. 57 (2016) 2 - p. 255-265 , 2016

Link: https://doi.org/10.1002/..

12

Population Pharmacokinetic (PK) Evaluation and Missed Dose ..:

Sunkaraneni, Soujanya ; Phillips, Luann ; Chudasama, Vaishali...
Neurology. 84 (2015) 14_supplement - p. , 2015

Link: https://doi.org/10.1212/..

13

A Comparison of the Pharmacokinetic Profile of an Ascending..:

Darwish, Mona ; Bond, Mary ; Ricciotti, Nancy...
Reproductive Sciences. 21 (2014) 11 - p. 1401-1410 , 2014

Link: https://doi.org/10.1177/..

14

Introduction to population pharmacokinetic/pharmacodynamic ..:

Owen, Joel S ; Fiedler-Kelly, Jill , 2014

Link: https://onlinelibrary.wi..

15

Population Pharmacokinetic Modeling of LY2189102 after Mult..:

Bihorel, Sébastien ; Fiedler-Kelly, Jill ; Ludwig, Elizabeth..
The AAPS Journal. 16 (2014) 5 - p. 1009-1017 , 2014

Link: https://doi.org/10.1208/..